Curated News
By: NewsRamp Editorial Staff
May 20, 2025
Quantum BioPharma Signs Agreement for Lucid-MS IND Application
TLDR
- Quantum BioPharma gains advantage by signing agreement for Lucid-MS IND application, positioning for Phase 2 clinical trial for multiple sclerosis treatment.
- Quantum BioPharma partners with global CRO to submit Lucid-MS IND to FDA in Q4 2025, aiming to prevent demyelination in MS and neurodegenerative disorders.
- Quantum BioPharma's Lucid-MS therapy could improve lives by halting myelin degradation, offering hope for better treatments in neurodegenerative diseases like MS.
- Quantum BioPharma's innovative approach to neuroprotection with Lucid-MS shows promise in addressing the complex mechanisms of multiple sclerosis and other disorders.
Impact - Why it Matters
This news is significant as it highlights Quantum BioPharma's progress in developing a novel therapy for multiple sclerosis, addressing a critical need for neuroprotective treatments. The agreement with a contract research organization marks a crucial step towards initiating a Phase 2 clinical trial, potentially offering new hope for patients with MS and other related disorders.
Summary
Quantum BioPharma (NASDAQ: QNTM) has signed an agreement with a global pharmaceutical contract research organization to prepare an Investigational New Drug (IND) application for its lead compound, Lucid-21-302 (Lucid-MS), targeting multiple sclerosis. The IND submission to the FDA is planned for the fourth quarter of 2025 and, if accepted, would enable the company to initiate a Phase 2 clinical trial. Lucid-21-302 is a patented, non-immunomodulatory neuroprotective therapy shown in preclinical studies to prevent demyelination, a key driver of MS and other neurodegenerative disorders.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Quantum BioPharma Signs Agreement for Lucid-MS IND Application
